Impact of High-Dose Atorvastatin Therapy and Clinical Risk Factors on Incident Aortic Valve Stenosis in Patients With Cardiovascular Disease (from TNT, IDEAL, and SPARCL)

详细信息    查看全文

• 作者：Benoit J. Arsenault ; PhD^a ; S. Matthijs Boekholdt ; MD ; PhD^b ; Samia Mora ; MD ; MHS^c ; David A. DeMicco ; PharmD^d ; Weihang Bao ; PhD^d ; Jean-Claude Tardif ; MD^a ; Pierre Amarenco ; MD ; PhD^e ; Terje Pedersen ; PhD ; MD^f ; Philip Barter ; MD ; PhD^g ; David D. Waters ; MD^h ; ^{dwaters@medsfgh.ucsf.edu" class="auth_mail}
• 刊名：The American Journal of Cardiology
• 出版年：15 April, 2014
• 年：2014
• 卷：113
• 期：8
• 页码：1378-1382
• 全文大小：131 K

文摘

Clinical trials have not provided evidence for a role of statin therapy in reducing aortic valve stenosis (AVS) severity in patients with documented AVS. However, whether statin therapy could prevent the onset of AVS is unknown. Our objectives were (1) to compare the incidence rates of AVS among patients treated with high-dose versus usual-dose statin or placebo and (2) to identify clinical risk factors associated with the development of AVS. We conducted post hoc analyses in 23,508 participants from 3 large-scale multicenter atorvastatin randomized blinded clinical trials: Treating to New Targets, the Incremental Decrease in End Points Through Aggressive Lipid Lowering, and the Stroke Prevention by Aggressive Reduction in Cholesterol Levels. The main outcome measure was the incidence of clinical AVS over a median follow-up of 4.9聽years (82 cases). Among patients who developed AVS, 39 (47.6%) were treated with atorvastatin 80聽mg and 43 (52.4%) were treated with lower dose statin (atorvastatin 10聽mg in Treating to New Targets, simvastatin 20 to 40聽mg in Incremental Decrease in End Points Through Aggressive Lipid Lowering, or placebo in Stroke Prevention by Aggressive Reduction in Cholesterol Levels; hazard ratio [HR] 0.91, 95% confidence interval [CI] 0.59 to 1.41, p聽= 0.67). In multivariate analyses forcing treatment, sex, and race into the model, factors that were significantly associated with AVS included age (HR 2.17, 95% CI 1.61 to 2.93, p <0.0001 per 1-SD increment), diabetes (HR 1.67, 95% CI 1.00 to 2.80, p聽= 0.05), vitamin K antagonist use (HR 3.25, 95% CI 2.06 to 5.16, p <0.0001), and previous statin use (HR 2.65, 95% CI 1.54 to 4.60, p聽= 0.0008). In conclusion, random allocation to high-dose versus usual-dose statin therapy or placebo did not impact the incidence of AVS among patients without known AVS. Age, diabetes, vitamin K antagonists, and previous statin use were significant predictors of incident AVS in these high-risk patients.